KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBITDA (2016 - 2025)

Historic EBITDA for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to -$13.4 million.

  • Neogenomics' EBITDA rose 2710.18% to -$13.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$115.9 million, marking a year-over-year decrease of 2581.27%. This contributed to the annual value of -$115.9 million for FY2025, which is 2581.27% down from last year.
  • According to the latest figures from Q4 2025, Neogenomics' EBITDA is -$13.4 million, which was up 2710.18% from -$27.0 million recorded in Q3 2025.
  • Over the past 5 years, Neogenomics' EBITDA peaked at -$13.4 million during Q4 2025, and registered a low of -$52.0 million during Q1 2022.
  • For the 5-year period, Neogenomics' EBITDA averaged around -$29.6 million, with its median value being -$27.4 million (2025).
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 95056.76% in 2021, then skyrocketed by 3876.23% in 2023.
  • Neogenomics' EBITDA (Quarter) stood at -$41.6 million in 2021, then soared by 36.53% to -$26.4 million in 2022, then rose by 29.6% to -$18.6 million in 2023, then rose by 0.93% to -$18.4 million in 2024, then grew by 27.1% to -$13.4 million in 2025.
  • Its last three reported values are -$13.4 million in Q4 2025, -$27.0 million for Q3 2025, and -$47.6 million during Q2 2025.